晚期癌症存在性痛苦:短期心理动力治疗与常规心理肿瘤治疗的实用随机对照试验方案
本研究为双臂平行随机对照试验,纳入160例伴临床显著存在性痛苦的III/IV期实体瘤或晚期血液肿瘤患者,比较短期心理动力治疗(ORPHYS)与常规心理肿瘤治疗(TAU)的效果。主要结局为6个月随访时的去道德化(Demoralization Scale-II),次要结局包括情感、焦虑及应激相关障碍诊断、死亡焦虑、尊严相关痛苦和生活质量。
要点
- ORPHYS为手册化个体面对面心理治疗,针对癌症患者疾病情境中的情绪与关系冲突。
- TAU包括至少一次由有心理肿瘤经验医师或心理学家提供的个体治疗。
- 主要结局为基线后6个月随访时去道德化量表II评分组间差异。
核心结论
- 旨在评估ORPHYS相比TAU减轻晚期癌症患者存在性痛苦的有效性。
研究设计与样本
- 双臂平行随机对照试验,主动对照组,目标样本量160例。
- 招募伴临床显著存在性痛苦的III/IV期实体瘤或晚期血液肿瘤患者。
- 招募地点为德国汉堡、杜塞尔多夫和维尔茨堡综合癌症中心。
- ORPHYS为手册化个体面对面心理治疗,持续5至11个月,每周1次共15至31次,每次50分钟。
- TAU包括至少一次由有心理肿瘤经验医师或心理学家提供的个体治疗。
关键数值与推荐
- 主要结局为去道德化,采用Demoralization Scale-II评估。
- 次要结局包括情感、焦虑及应激相关障碍诊断、死亡焦虑、尊严相关痛苦和生活质量。
- 基线前及基线后3、6、9、12个月进行评估,采用线性混合模型比较组间差异。
- 对基线后6个月随访时的组间对比进行确证性检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As improvements in anti-cancer treatments have extended survival, patients with advanced cancer and their family caregivers face existential tension between engaging in life and coping with uncertainty about illness trajectory and the course of treatment. For a subgroup, this tension is associated with overwhelming fear and existential distress. Such adjustment difficulties may increase the risk of mental disorders, poor quality of life, and suicidality, and impair prognostic awareness and patient-clinician communication. Despite growing interest in open conversations about end-of-life issues, systematic evidence on effective psychotherapies to best support psychological adaptation in patients with high levels of existential distress is still scarce. We aim to evaluate the effectiveness of a short-term psychodynamic therapy (ORPHYS) to mitigate existential distress compared to usual psycho-oncological treatment (TAU). METHODS: We conduct a two-arm parallel randomized controlled trial with an active control group. ORPHYS is a manualized individual face-to-face psychotherapy focusing on emotional and relational conflicts specific to cancer patients' illness situation. Treatment lasts between 5 and 11 months with 15 to 31 weekly sessions (50 min). TAU includes at least one individual session provided by physicians or psychologists with experience in psycho-oncological care. Patients will be assessed pre-intervention and 3, 6, 9, and 12 months after baseline. Target sample size is 160 randomized participants. We recruit patients with stage III/IV solid tumors or advanced hematological cancer and clinically significant existential distress from psycho-oncology clinics and referring oncologists at Hamburg, Düsseldorf, and Würzburg Comprehensive Cancer Centers, Germany. The primary outcome is demoralization (Demoralization Scale-II). Secondary outcomes include diagnoses of affective, anxiety and stress-related disorders, death anxiety, dignity-related distress, and quality of life. Outcome assessments are conducted via self-report questionnaires and diagnostic interviews. Linear mixed models examine outcome differences between trial arms. A confirmatory test of the group contrast at 6-month follow-up after baseline is conducted. DISCUSSION: Due to an aging population and prolonged survival, there is a growing demand to help patients deal with existential challenges undergoing palliative cancer care. The study will contribute to knowledge about how clinicians can best help patients with advanced cancer who substantially struggle with uncertainty at the end of life. TRIAL REGISTRATION: German Clinical Trials Registry, DRKS00038173. Registered October 20th, 2025, https://drks.de/search/en/trial/DRKS00038173 . CLINICALTRIALS: gov, NCT07312760. Registered December 30, 2025, https://clinicaltrials.gov/study/NCT07312760 .
引用
- Philipp R, Walbaum C, Bokemeyer C, et al. Existential distress in advanced cancer: study protocol of a pragmatic randomized controlled trial of a short-term psychodynamic therapy (ORPHYS) compared to usual psycho-oncological treatment (TAU). Trials. 2026. PMID: 42098804. doi:10.1186/s13063-026-09744-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。